Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to
نویسندگان
چکیده
Sakonjo, Shokei-Kim, Kunio Matsumoto, Toshikazu Nakamura, Jitsuo Higaki and Toshio Yoshiaki Taniyama, Ryuichi Morishita, Hironori Nakagami, Atsushi Moriguchi, Hiroshi Hamsters Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2000 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/01.CIR.102.2.246 2000;102:246-252 Circulation. http://circ.ahajournals.org/content/102/2/246 World Wide Web at: The online version of this article, along with updated information and services, is located on the
منابع مشابه
Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters.
BACKGROUND Because hepatocyte growth factor (HGF) prevented and/or regressed fibrosis in liver and pulmonary injury models, HGF may play an important role in the pathogenesis of fibrotic cardiovascular disease. Because angiotensin (Ang) II significantly decreased local HGF production, we performed (1) in vitro experiments using fibroblasts and (2) administration of an ACE inhibitor (temocapril)...
متن کاملAngiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy.
Impairment of cardiac function in cardiomyopathy has been postulated to be related to decreased blood blow and increased collagen synthesis. Therefore, a therapeutic approach to alter the blood flow or fibrosis directly by means of growth factors may open a new therapeutic concept in dilated cardiomyopathy. From this viewpoint, hepatocyte growth factor (HGF) is a unique growth factor with antif...
متن کاملTelmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Angiotensin (Ang) II type 1 receptor blockers have demonstrated beneficial effects beyond blood pressure control in the treatment of chronic kidney disease. There is clinical evidence that telmisartan is more effective than losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, because it is a partial agonist of peroxisome-proliferator activated receptor-γ (PPARγ),...
متن کاملHepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts.
Structural remodeling of the myocardium, including myocyte hypertrophy, myocardial fibrosis, and dilatation, drives functional impairment in various forms of acquired and hereditary cardiomyopathy. Using cardiomyopathic Syrian hamsters with a genetic defect in delta-sarcoglycan, we investigated the potential involvement of hepatocyte growth factor (HGF) in the pathophysiology and therapeutics r...
متن کاملAntifibrotic therapies to control cardiac fibrosis
Cardiac fibrosis occurs naturally after myocardial infarction. While the initially formed fibrotic tissue prevents the infarcted heart tissue from rupture, the progression of cardiac fibrosis continuously expands the size of fibrotic tissue and causes cardiac function decrease. Cardiac fibrosis eventually evolves the infarcted hearts into heart failure. Inhibiting cardiac fibrosis from progress...
متن کامل